Serious & Notifiable Infections — MCQs
On this page
A 40-year-old woman with rheumatoid arthritis treated with methotrexate and infliximab undergoes screening for latent tuberculosis before starting therapy. Her Mantoux test shows 8 mm induration, and interferon-gamma release assay (IGRA) is positive. Chest X-ray is normal. She has no symptoms of active TB. What is the most appropriate management?
A 5-year-old girl is brought to the emergency department with a 4-hour history of high fever, drowsiness, and a non-blanching purpuric rash on her legs and trunk. She is tachycardic with a capillary refill time of 4 seconds. Blood pressure is 85/50 mmHg. Blood cultures are taken and she is given immediate intravenous ceftriaxone. Which statutory notification requirement applies in this case?
A 35-year-old asylum seeker from Eritrea presents with a 2-month history of cough, weight loss, and fever. Chest X-ray shows bilateral upper lobe cavitation. Sputum microscopy reveals acid-fast bacilli. He has no known drug allergies and HIV test is negative. What is the most appropriate initial treatment regimen for this patient?
A 52-year-old man from Pakistan with newly diagnosed smear-positive pulmonary tuberculosis requires treatment. He has HIV coinfection (CD4 200 cells/mm³) and is taking tenofovir/emtricitabine/efavirenz. He also has chronic hepatitis B, hypertension (amlodipine 5mg daily), and epilepsy well-controlled on phenytoin 300mg daily. Initial ALT is 65 U/L, bilirubin 18 µmol/L. What is the most critical drug interaction requiring immediate management modification?
A 60-year-old man presents with progressive confusion, fever, and left-sided weakness over 3 days. MRI brain shows asymmetrical temporal lobe changes with haemorrhagic features. Lumbar puncture reveals: opening pressure 18 cmH2O, CSF red blood cells 850/mm³, white cells 245/mm³ (75% lymphocytes), protein 0.9 g/L, glucose 3.8 mmol/L (plasma glucose 5.5 mmol/L). CSF PCR for herpes simplex virus is positive. Despite intravenous aciclovir for 5 days, he remains confused with worsening seizures. What is the most appropriate next management step?
A 29-year-old woman completes 6 months of treatment for drug-sensitive pulmonary tuberculosis with documented sputum culture conversion at 2 months. She is now asymptomatic with a normal chest X-ray. She wishes to conceive. She asks about the risk of TB recurrence during pregnancy and the safety of becoming pregnant. What is the most appropriate counselling regarding her conception plans?
A 45-year-old woman with miliary tuberculosis is started on standard four-drug therapy. After 3 weeks of treatment, she develops confusion, ataxia, and ophthalmoplegia. Her serum sodium is 128 mmol/L, ALT is 45 U/L (baseline 35 U/L), and serum lactate is 4.2 mmol/L. Brain MRI shows bilateral symmetrical lesions in the mamillary bodies and thalamus. Which anti-tuberculous drug is most likely responsible for this presentation?
A 72-year-old man develops acute bacterial meningitis and is treated with intravenous ceftriaxone and dexamethasone. Blood cultures grow Streptococcus pneumoniae with penicillin MIC of 2 mg/L. His clinical condition improves over 48 hours. CSF culture at 48 hours shows continued growth of the organism. What is the most appropriate modification to his antibiotic regimen?
A 38-year-old man with newly diagnosed HIV (CD4 count 120 cells/mm³) presents with fever, cough, and weight loss. Chest X-ray shows bilateral upper lobe infiltrates with cavitation. Three sputum samples are AFB smear-positive, and culture confirms Mycobacterium tuberculosis fully sensitive to first-line drugs. He is started on standard TB treatment. When should antiretroviral therapy (ART) be initiated?
A 3-month-old infant is brought to the emergency department with fever of 38.8°C, irritability, poor feeding, and a bulging fontanelle. Blood tests show: WBC 18.5 × 10⁹/L (neutrophils 15.2 × 10⁹/L), CRP 145 mg/L. Lumbar puncture reveals CSF white cells 1200/mm³ (85% neutrophils), protein 1.8 g/L, glucose 1.5 mmol/L (plasma glucose 4.8 mmol/L). Gram stain shows Gram-positive cocci in chains. What is the most appropriate antibiotic regimen?
Serious & Notifiable Infections UK Medical PG Practice Questions and MCQs
Question 231: A 40-year-old woman with rheumatoid arthritis treated with methotrexate and infliximab undergoes screening for latent tuberculosis before starting therapy. Her Mantoux test shows 8 mm induration, and interferon-gamma release assay (IGRA) is positive. Chest X-ray is normal. She has no symptoms of active TB. What is the most appropriate management?
- A. Start anti-TNF therapy immediately as the chest X-ray is normal
- B. Commence isoniazid for 6 months before starting anti-TNF therapy (Correct Answer)
- C. Commence full four-drug anti-tuberculous therapy for 6 months before starting anti-TNF therapy
- D. Repeat the Mantoux test in 4 weeks to confirm the result
- E. Perform a CT chest and bronchoscopy before making any treatment decisions
Explanation: ***Commence isoniazid for 6 months before starting anti-TNF therapy*** - A **positive IGRA** and a Mantoux test of **8 mm** in an immunosuppressed patient indicate **latent tuberculosis infection (LTBI)**, requiring prophylaxis before starting biologics. - Treating LTBI with **isoniazid (plus pyridoxine)** significantly reduces the risk of **TB reactivation**, which is a known complication of **anti-TNF** drugs like infliximab. *Start anti-TNF therapy immediately as the chest X-ray is normal* - A normal chest X-ray excludes active pulmonary disease but does not rule out **latent infection**, which can flare once **TNF-alpha** is inhibited. - Starting biologics without treating LTBI carries a high risk of life-threatening **disseminated tuberculosis** or miliary TB. *Commence full four-drug anti-tuberculous therapy for 6 months before starting anti-TNF therapy* - Full four-drug therapy (RIPE) is strictly reserved for **active tuberculosis** disease, which is not present here given the lack of symptoms and normal X-ray. - For LTBI, **monotherapy** (e.g., isoniazid) or dual therapy (e.g., rifampicin and isoniazid) is the standard of care to minimize **drug toxicity**. *Repeat the Mantoux test in 4 weeks to confirm the result* - Repeating the test is unnecessary because the **IGRA is already positive**, providing a more specific confirmation of infection than the Mantoux test. - In patients already on **methotrexate**, the skin test may even be **falsely negative** due to anergy, making any positive result clinically significant. *Perform a CT chest and bronchoscopy before making any treatment decisions* - These invasive or high-radiation investigations are not indicated when the patient has a **normal chest X-ray** and is **asymptomatic**. - Guidelines prioritize starting **chemoprophylaxis** based on immunological evidence (IGRA/TST) rather than searching for subclinical active disease via bronchoscopy.
Question 232: A 5-year-old girl is brought to the emergency department with a 4-hour history of high fever, drowsiness, and a non-blanching purpuric rash on her legs and trunk. She is tachycardic with a capillary refill time of 4 seconds. Blood pressure is 85/50 mmHg. Blood cultures are taken and she is given immediate intravenous ceftriaxone. Which statutory notification requirement applies in this case?
- A. Notification to the UK Health Security Agency must be made within 3 working days of clinical diagnosis
- B. Notification to the local Proper Officer must be made upon clinical suspicion, without waiting for laboratory confirmation (Correct Answer)
- C. Notification is only required once laboratory confirmation of Neisseria meningitidis is obtained
- D. Notification should be made to the General Medical Council within 24 hours
- E. Notification is the responsibility of the microbiologist once blood culture results are available
Explanation: ***Notification to the local Proper Officer must be made upon clinical suspicion, without waiting for laboratory confirmation*** - Registered medical practitioners have a **statutory duty** to notify the **Proper Officer** (at the UK Health Security Agency) immediately upon clinical suspicion of a notifiable disease like **meningococcal septicaemia**, due to the rapid progression and high mortality. - Urgent notification allows for rapid **public health intervention**, such as identification of close contacts and administration of **chemoprophylaxis** to prevent further cases, which is critical in a serious condition like this. *Notification to the UK Health Security Agency must be made within 3 working days of clinical diagnosis* - While some notifications are non-urgent, suspected **meningococcal disease** requires **immediate notification** (usually within 24 hours or sooner) due to its life-threatening nature and potential for rapid spread. - Waiting **3 working days** would cause a dangerous and unacceptable delay in tracing contacts and providing necessary antibiotic prophylaxis, significantly increasing the risk of further morbidity and mortality. *Notification is only required once laboratory confirmation of Neisseria meningitidis is obtained* - Clinical suspicion alone, based on signs like high fever, drowsiness, and a **non-blanching purpuric rash**, is the legal trigger for notification, as waiting for **laboratory confirmation** like blood cultures delays crucial public health action. - The **Health Protection Regulations 2010** explicitly state that notification should not be delayed for definitive microbiology results, as early intervention is paramount. *Notification should be made to the General Medical Council within 24 hours* - The **General Medical Council (GMC)** is a regulatory body for doctors and does not handle **public health notifications** or infectious disease surveillance. - Sending notifications to the GMC instead of the **local Health Protection Team** or **Proper Officer** would prevent the necessary local outbreak management protocols from starting, endangering public health. *Notification is the responsibility of the microbiologist once blood culture results are available* - While laboratories have a separate duty to notify of identified organisms, the **primary responsibility** for notifying suspected clinical cases rests with the **attending clinician**. - Relying solely on the **microbiologist** would miss the opportunity for early intervention during the crucial window before laboratory results are finalized, which can take days.
Question 233: A 35-year-old asylum seeker from Eritrea presents with a 2-month history of cough, weight loss, and fever. Chest X-ray shows bilateral upper lobe cavitation. Sputum microscopy reveals acid-fast bacilli. He has no known drug allergies and HIV test is negative. What is the most appropriate initial treatment regimen for this patient?
- A. Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, followed by rifampicin and isoniazid for 4 months (Correct Answer)
- B. Rifampicin, isoniazid, and pyrazinamide for 6 months
- C. Rifampicin and isoniazid for 9 months
- D. Rifampicin, isoniazid, pyrazinamide, ethambutol, and streptomycin for 2 months, followed by rifampicin, isoniazid, and ethambutol for 10 months
- E. Moxifloxacin, isoniazid, pyrazinamide, and ethambutol for 6 months
Explanation: ***Rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, followed by rifampicin and isoniazid for 4 months*** - This is the standard **6-month first-line regimen** for **drug-sensitive pulmonary tuberculosis**, consisting of an initial **intensive phase** with four drugs (RIPE) and a **continuation phase** with two drugs (RI). - The inclusion of **ethambutol** in the initial phase is crucial, especially in patients from high-prevalence areas like Eritrea, to cover for potential **isoniazid resistance** until drug susceptibility results are available. *Rifampicin, isoniazid, and pyrazinamide for 6 months* - This regimen lacks **ethambutol** in the initial intensive phase, which is important for preventing development of **drug resistance** and ensuring adequate coverage against potentially resistant strains. - Omitting ethambutol without confirmed drug susceptibility can lead to a higher risk of **treatment failure** or selection of **multidrug-resistant TB (MDR-TB)**. *Rifampicin and isoniazid for 9 months* - This regimen lacks **pyrazinamide** and **ethambutol** in the initial phase, making it less effective in sterilizing lesions and preventing resistance, respectively. - A **9-month duration** with only two drugs for the entire course is an outdated and suboptimal approach for active pulmonary TB, leading to slower bacillary clearance and higher **relapse rates**. *Rifampicin, isoniazid, pyrazinamide, ethambutol, and streptomycin for 2 months, followed by rifampicin, isoniazid, and ethambutol for 10 months* - **Streptomycin**, an injectable agent, is typically reserved for specific forms of **drug-resistant TB** or in cases of severe intolerance to oral drugs, due to its significant **ototoxicity** and **nephrotoxicity**. - A **12-month total duration** is excessively long for routine drug-sensitive pulmonary TB and is usually reserved for complex cases such as **TB meningitis** or disseminated disease. *Moxifloxacin, isoniazid, pyrazinamide, and ethambutol for 6 months* - **Moxifloxacin** (a fluoroquinolone) is not a first-line antitubercular drug for drug-sensitive TB but is reserved for **drug-resistant TB** or in patients who cannot tolerate **rifampicin**. - Substituting **rifampicin**, a cornerstone of first-line therapy, with moxifloxacin without a clinical indication for drug resistance is inappropriate and can compromise treatment efficacy.
Question 234: A 52-year-old man from Pakistan with newly diagnosed smear-positive pulmonary tuberculosis requires treatment. He has HIV coinfection (CD4 200 cells/mm³) and is taking tenofovir/emtricitabine/efavirenz. He also has chronic hepatitis B, hypertension (amlodipine 5mg daily), and epilepsy well-controlled on phenytoin 300mg daily. Initial ALT is 65 U/L, bilirubin 18 µmol/L. What is the most critical drug interaction requiring immediate management modification?
- A. Rifampicin will reduce efavirenz levels requiring dose adjustment of antiretroviral therapy
- B. Rifampicin will reduce phenytoin levels significantly increasing seizure risk (Correct Answer)
- C. Isoniazid and rifampicin together create high hepatotoxicity risk with pre-existing liver disease
- D. Rifampicin will reduce amlodipine levels causing inadequate blood pressure control
- E. Pyrazinamide will worsen hepatitis B liver disease requiring modified TB regimen
Explanation: ***Rifampicin will reduce phenytoin levels significantly increasing seizure risk*** - **Rifampicin** is a potent **CYP450 enzyme inducer** that markedly increases the metabolism of **phenytoin**, potentially reducing its plasma levels by 50-75%. - This drug interaction presents an immediate life-threatening risk of **breakthrough seizures**, necessitating urgent dose adjustment or a switch to non-enzyme-dependent agents like **levetiracetam**. *Rifampicin will reduce efavirenz levels requiring dose adjustment of antiretroviral therapy* - While **rifampicin** does lower **efavirenz** concentrations, clinical practice (including UK guidelines) generally maintains a standard 600mg dose of efavirenz because levels often remain therapeutic. - This interaction is clinically monitored via viral load but is less immediately critical than the urgent risk of status epilepticus from sub-therapeutic phenytoin. *Isoniazid and rifampicin together create high hepatotoxicity risk with pre-existing liver disease* - Although these drugs are **hepatotoxic**, the patient's baseline **ALT (65 U/L)** is less than three times the upper limit of normal, allowing for standard therapy with close monitoring. - It is a significant long-term management consideration but does not constitute an immediate emergency compared to the loss of seizure control. *Rifampicin will reduce amlodipine levels causing inadequate blood pressure control* - **Rifampicin** induces the metabolism of **calcium channel blockers** like **amlodipine**, which may lead to suboptimal blood pressure control. - This is a manageable chronic issue and does not carry the same degree of acute morbidity as an uncontrolled seizure disorder. *Pyrazinamide will worsen hepatitis B liver disease requiring modified TB regimen* - **Pyrazinamide** is indeed the most hepatotoxic agent in the RIPE regimen, but it does not specifically worsen the viral progression of **Hepatitis B**. - Standard TB regimens are generally initiated in such patients unless there is evidence of severe **liver failure** (e.g., elevated bilirubin or prolonged PT).
Question 235: A 60-year-old man presents with progressive confusion, fever, and left-sided weakness over 3 days. MRI brain shows asymmetrical temporal lobe changes with haemorrhagic features. Lumbar puncture reveals: opening pressure 18 cmH2O, CSF red blood cells 850/mm³, white cells 245/mm³ (75% lymphocytes), protein 0.9 g/L, glucose 3.8 mmol/L (plasma glucose 5.5 mmol/L). CSF PCR for herpes simplex virus is positive. Despite intravenous aciclovir for 5 days, he remains confused with worsening seizures. What is the most appropriate next management step?
- A. Continue aciclovir for full 14-day course as initial improvement takes time
- B. Switch from intravenous aciclovir to oral valaciclovir for better CNS penetration
- C. Add foscarnet to the treatment regimen due to possible aciclovir resistance (Correct Answer)
- D. Stop aciclovir and start ganciclovir for possible CMV encephalitis
- E. Increase the dose of aciclovir to 15 mg/kg three times daily
Explanation: ***Add foscarnet to the treatment regimen due to possible aciclovir resistance*** - Clinical deterioration or lack of improvement after 5 days of appropriate therapy for **HSV encephalitis** suggests **aciclovir resistance**, handled by adding **foscarnet**. - **Foscarnet** inhibits viral DNA polymerase directly without requiring activation by **viral thymidine kinase**, circumventing the most common mechanism of resistance. *Continue aciclovir for full 14-day course as initial improvement takes time* - While a standard course is 14–21 days, **worsening seizures** and persistent confusion after 5 days of therapy indicate a failure of the current regimen. - Delaying alternative treatments in the face of clinical decline increases the risk of permanent **neurological damage**. *Switch from intravenous aciclovir to oral valaciclovir for better CNS penetration* - **Intravenous aciclovir** is the gold standard for CNS infections; oral medications cannot consistently achieve the high plasma concentrations required. - **Valaciclovir** is a prodrug of aciclovir and would not address the issue if the underlying strain is already **aciclovir-resistant**. *Stop aciclovir and start ganciclovir for possible CMV encephalitis* - This patient has a **positive PCR for HSV**, making **CMV encephalitis** an unlikely primary diagnosis. - **Ganciclovir** and aciclovir share similar phosphorylation pathways (via viral kinases), meaning resistance to aciclovir often confers cross-resistance to ganciclovir. *Increase the dose of aciclovir to 15 mg/kg three times daily* - The standard dose for encephalitis is **10 mg/kg**, and failure at this dose is more likely due to **resistance** than inadequate serum levels. - Simply increasing the dose of the same drug is unlikely to overcome a resistant **thymidine kinase-deficient** viral strain.
Question 236: A 29-year-old woman completes 6 months of treatment for drug-sensitive pulmonary tuberculosis with documented sputum culture conversion at 2 months. She is now asymptomatic with a normal chest X-ray. She wishes to conceive. She asks about the risk of TB recurrence during pregnancy and the safety of becoming pregnant. What is the most appropriate counselling regarding her conception plans?
- A. She should wait 12 months after treatment completion before conceiving due to high risk of relapse
- B. She can conceive immediately as treatment is complete and risk of relapse is low (Correct Answer)
- C. She should wait 6 months after treatment completion and undergo repeat sputum cultures before conceiving
- D. She should avoid pregnancy indefinitely due to risk of reactivation during immunosuppression of pregnancy
- E. She should wait 24 months after treatment completion to ensure no late relapse
Explanation: ***She can conceive immediately as treatment is complete and risk of relapse is low***- After completing a **full course** of treatment for **drug-sensitive TB** with documented **sputum culture conversion**, the risk of relapse is very low (approx. 2-3%).- Modern guidelines do not require a waiting period post-treatment, and **pregnancy** is not a significant risk factor for reactivation in patients who have been successfully cured.*She should wait 12 months after treatment completion before conceiving due to high risk of relapse*- There is no clinical evidence to support a **12-month delay**, as the majority of relapses occur shortly after treatment if they are to happen at all.- Mandating a year of waiting causes unnecessary psychological distress and is not supported by **WHO** or **UK guidelines**.*She should wait 6 months after treatment completion and undergo repeat sputum cultures before conceiving*- Routine **repeat sputum cultures** are not recommended for **asymptomatic** patients who have already achieved culture conversion and completed therapy.- A **6-month waiting period** is arbitrary and does not provide additional safety benefits for a patient who is clinically and radiologically well.*She should avoid pregnancy indefinitely due to risk of reactivation during immunosuppression of pregnancy*- Historical beliefs that **pregnancy-related immunosuppression** significantly increases TB reactivation risk have been largely refuted by current evidence.- Successful treatment effectively **eliminates the pathogen**, allowing the patient to have a safe pregnancy with no increased risk to the fetus.*She should wait 24 months after treatment completion to ensure no late relapse*- A **24-month delay** is only typically relevant in cases of **Multi-Drug Resistant (MDR-TB)**, where follow-up periods are longer due to higher failure rates.- For standard **drug-sensitive pulmonary TB**, waiting two years is disproportionate and medically unnecessary given the high success rate of the 6-month regimen.
Question 237: A 45-year-old woman with miliary tuberculosis is started on standard four-drug therapy. After 3 weeks of treatment, she develops confusion, ataxia, and ophthalmoplegia. Her serum sodium is 128 mmol/L, ALT is 45 U/L (baseline 35 U/L), and serum lactate is 4.2 mmol/L. Brain MRI shows bilateral symmetrical lesions in the mamillary bodies and thalamus. Which anti-tuberculous drug is most likely responsible for this presentation?
- A. Rifampicin
- B. Isoniazid (Correct Answer)
- C. Pyrazinamide
- D. Ethambutol
- E. Streptomycin
Explanation: ***Isoniazid*** - **Isoniazid** can cause **Wernicke's encephalopathy** (confusion, ataxia, ophthalmoplegia) by interfering with **thiamine (Vitamin B1) metabolism**, particularly in malnourished individuals or those with increased metabolic demand like miliary tuberculosis. - The characteristic MRI findings of bilateral symmetrical lesions in the **mamillary bodies** and **thalamus**, along with **elevated serum lactate**, are hallmarks of severe thiamine deficiency, as thiamine is a critical cofactor in carbohydrate metabolism (e.g., pyruvate dehydrogenase). *Rifampicin* - Primarily associated with **hepatotoxicity** (though ALT elevation here is mild) and **orange discoloration of body fluids**. - It is a potent **CYP450 inducer** but does not typically cause acute neurological syndromes like Wernicke's encephalopathy or interfere with thiamine metabolism. *Pyrazinamide* - Common side effects include **hepatotoxicity** (often dose-related) and **hyperuricemia**, which can precipitate gout. - It does not cause central nervous system lesions, ophthalmoplegia, or interfere with thiamine pathways leading to lactic acidosis. *Ethambutol* - The most significant adverse effect is **optic neuritis**, leading to decreased visual acuity and **red-green color blindness**. - It does not present with confusion, ataxia, or the specific MRI findings observed in this patient's brain. *Streptomycin* - As an aminoglycoside, its primary toxicities include **ototoxicity** (vestibular and auditory damage) and **nephrotoxicity**. - It is not implicated in causing metabolic encephalopathy, thiamine deficiency, or the specific neurological symptoms and MRI findings seen in Wernicke's encephalopathy.
Question 238: A 72-year-old man develops acute bacterial meningitis and is treated with intravenous ceftriaxone and dexamethasone. Blood cultures grow Streptococcus pneumoniae with penicillin MIC of 2 mg/L. His clinical condition improves over 48 hours. CSF culture at 48 hours shows continued growth of the organism. What is the most appropriate modification to his antibiotic regimen?
- A. Continue current regimen as clinical improvement suggests adequate treatment
- B. Add vancomycin to the current regimen (Correct Answer)
- C. Switch from ceftriaxone to high-dose benzylpenicillin
- D. Add rifampicin to the current regimen
- E. Stop dexamethasone and increase ceftriaxone dose
Explanation: ***Add vancomycin to the current regimen*** - The persistent growth of **Streptococcus pneumoniae** in the CSF after 48 hours, despite clinical improvement, signifies microbiological treatment failure, especially given the **penicillin MIC of 2 mg/L**. - **Vancomycin** is crucial for covering penicillin- and cephalosporin-resistant pneumococci in meningitis, and its addition ensures bactericidal activity against the persistent pathogen. *Continue current regimen as clinical improvement suggests adequate treatment* - Clinical improvement alone is insufficient when there is **persistent bacterial growth** in the CSF, which indicates ongoing infection and a high risk of relapse and neurological sequelae. - The **penicillin MIC of 2 mg/L** suggests intermediate resistance, meaning the current ceftriaxone monotherapy may not be fully effective in sterilizing the CSF. *Switch from ceftriaxone to high-dose benzylpenicillin* - A **penicillin MIC of 2 mg/L** for *S. pneumoniae* indicates intermediate resistance, making high-dose benzylpenicillin unlikely to achieve sufficient bactericidal concentrations in the CSF to eradicate the organism. - Ceftriaxone generally provides better **CSF penetration** and efficacy against *S. pneumoniae* with intermediate penicillin resistance compared to benzylpenicillin. *Add rifampicin to the current regimen* - While **rifampicin** can be used as an adjunctive agent for resistant pneumococcal meningitis, **vancomycin** is the preferred and guideline-recommended primary agent to add in this scenario of persistent growth. - Rifampicin use carries a risk of rapid development of **monotherapy resistance**, making it a secondary choice, often reserved for highly resistant strains or specific circumstances. *Stop dexamethasone and increase ceftriaxone dose* - **Dexamethasone** is vital in pneumococcal meningitis to reduce inflammation and improve neurological outcomes; stopping it prematurely is not advised. - Increasing the **ceftriaxone dose** alone is unlikely to overcome the established resistance indicated by persistent CSF growth and a significant MIC, requiring a different antibiotic with activity against resistant strains.
Question 239: A 38-year-old man with newly diagnosed HIV (CD4 count 120 cells/mm³) presents with fever, cough, and weight loss. Chest X-ray shows bilateral upper lobe infiltrates with cavitation. Three sputum samples are AFB smear-positive, and culture confirms Mycobacterium tuberculosis fully sensitive to first-line drugs. He is started on standard TB treatment. When should antiretroviral therapy (ART) be initiated?
- A. Immediately, concurrent with TB treatment
- B. After 2 weeks of TB treatment (Correct Answer)
- C. After 2 months of TB treatment when the intensive phase is complete
- D. After 6 months when TB treatment is complete
- E. ART should be deferred until CD4 count falls below 100 cells/mm³
Explanation: ***After 2 weeks of TB treatment*** - For patients with HIV and TB who have a **CD4 count between 50-200 cells/mm³**, guidelines recommend initiating ART within **2 to 8 weeks** of starting anti-tuberculosis therapy. - This approach balances the need to rapidly improve immune function and reduce HIV progression with minimizing the risk of **Immune Reconstitution Inflammatory Syndrome (IRIS)** and managing potential drug toxicities. *Immediately, concurrent with TB treatment* - Starting both regimens simultaneously significantly increases the risk of developing severe **Immune Reconstitution Inflammatory Syndrome (IRIS)**, especially with a low CD4 count. - It also makes it challenging to identify the source of **drug toxicities** if adverse effects occur, as both ART and TB drugs have overlapping side effect profiles. *After 2 months of TB treatment when the intensive phase is complete* - Delaying ART until the end of the **intensive phase** (2 months) is generally recommended for patients with higher **CD4 counts (>200 cells/mm³)** or in cases of **TB meningitis**. - For this patient with a **CD4 count of 120 cells/mm³**, a 2-month delay would unnecessarily prolong severe immunodeficiency and significantly increase the risk of **HIV disease progression** and mortality. *After 6 months when TB treatment is complete* - Deferring ART until **TB treatment is complete** (6 months) is associated with substantially **higher morbidity and mortality** in HIV-infected individuals, regardless of CD4 count. - This prolonged delay leaves the underlying **immunodeficiency** unaddressed, making the patient highly susceptible to other opportunistic infections and AIDS-related complications. *ART should be deferred until CD4 count falls below 100 cells/mm³* - Current HIV treatment guidelines recommend initiating ART for **all HIV-positive individuals**, regardless of their CD4 count, to preserve immune function and prevent disease progression. - Given the patient's existing low CD4 count of **120 cells/mm³** and active tuberculosis, further deferral would place them at a critical and unnecessary risk for **clinical deterioration** and life-threatening opportunistic infections.
Question 240: A 3-month-old infant is brought to the emergency department with fever of 38.8°C, irritability, poor feeding, and a bulging fontanelle. Blood tests show: WBC 18.5 × 10⁹/L (neutrophils 15.2 × 10⁹/L), CRP 145 mg/L. Lumbar puncture reveals CSF white cells 1200/mm³ (85% neutrophils), protein 1.8 g/L, glucose 1.5 mmol/L (plasma glucose 4.8 mmol/L). Gram stain shows Gram-positive cocci in chains. What is the most appropriate antibiotic regimen?
- A. Intravenous ceftriaxone alone
- B. Intravenous cefotaxime and amoxicillin (Correct Answer)
- C. Intravenous benzylpenicillin alone
- D. Intravenous ceftriaxone and vancomycin
- E. Intravenous cefotaxime and gentamicin
Explanation: ***Intravenous cefotaxime and amoxicillin*** - In infants under 3 months, **cefotaxime** is preferred over ceftriaxone because it does not displace bilirubin from albumin, avoiding the risk of **kernicterus**. - **Amoxicillin** must be added to the regimen to provide specific coverage for **Listeria monocytogenes**, an organism not covered by third-generation cephalosporins. *Intravenous ceftriaxone alone* - **Ceftriaxone** is generally avoided in neonates and very young infants due to its potential to cause **biliary sludging** and hyperbilirubinemia, leading to **kernicterus**. - This regimen lacks coverage for **Listeria monocytogenes**, which is a significant pathogen causing meningitis in infants under 3 months of age. *Intravenous benzylpenicillin alone* - While **benzylpenicillin** provides coverage for common Gram-positive cocci (like Group B Streptococcus), it lacks the necessary broad-spectrum coverage for important Gram-negative pathogens such as **E. coli**. - Given the high mortality of neonatal meningitis, **empiric therapy** must cover a wide range of common bacterial pathogens, which this single antibiotic does not achieve. *Intravenous ceftriaxone and vancomycin* - This regimen includes **ceftriaxone**, which is contraindicated in infants under 3 months due to the risk of **kernicterus**. - Although **vancomycin** covers resistant Gram-positives, this combination still does not provide adequate coverage for **Listeria monocytogenes**, a crucial pathogen in this age group. *Intravenous cefotaxime and gentamicin* - While **cefotaxime** is appropriate, **gentamicin** (an aminoglycoside) has poor penetration into the **cerebrospinal fluid (CSF)**, making it less effective for treating meningitis. - This combination also does not adequately cover **Listeria monocytogenes**, for which amoxicillin is specifically indicated in infants.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free